25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Hyundai Bioscience Co. Ltd
Buy, Hold or Sell?

Let's analyze Hyundai Bioscience Co. Ltd together

I guess you are interested in Hyundai Bioscience Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hyundai Bioscience Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Hyundai Bioscience Co. Ltd

I send you an email if I find something interesting about Hyundai Bioscience Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Hyundai Bioscience Co. Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Hyundai Bioscience Co. Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩1,520.24
Expected worth in 1 year
₩1,653.92
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
₩133.68
Return On Investment
0.9%

For what price can you sell your share?

Current Price per Share
₩14,250.00
Expected price per share
₩12,650 - ₩17,730
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Hyundai Bioscience Co. Ltd (5 min.)




Live pricePrice per Share (EOD)
₩14,250.00

2.2. Growth of Hyundai Bioscience Co. Ltd (5 min.)




Is Hyundai Bioscience Co. Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$42.3m$41.8m-$5.9m-16.4%

How much money is Hyundai Bioscience Co. Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$1.1m-$2.1m$989k86.0%
Net Profit Margin-144.9%-162.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Hyundai Bioscience Co. Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Hyundai Bioscience Co. Ltd?

Welcome investor! Hyundai Bioscience Co. Ltd's management wants to use your money to grow the business. In return you get a share of Hyundai Bioscience Co. Ltd.

First you should know what it really means to hold a share of Hyundai Bioscience Co. Ltd. And how you can make/lose money.

Speculation

The Price per Share of Hyundai Bioscience Co. Ltd is ₩14,250. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hyundai Bioscience Co. Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hyundai Bioscience Co. Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩1,520.24. Based on the TTM, the Book Value Change Per Share is ₩33.42 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-47.98 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hyundai Bioscience Co. Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.040.0%-0.030.0%-0.010.0%-0.040.0%-0.020.0%
Usd Book Value Change Per Share0.250.0%0.020.0%-0.030.0%0.010.0%0.020.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.250.0%0.020.0%-0.030.0%0.010.0%0.020.0%
Usd Price Per Share12.86-16.60-16.74-16.46-10.57-
Price to Earnings Ratio79.27-18.90--69.78--105.95-41.34-
Price-to-Total Gains Ratio51.79-5.50--306.64--587.45--56.13-
Price to Book Ratio12.08-18.75-16.12-17.01-13.34-
Price-to-Total Gains Ratio51.79-5.50--306.64--587.45--56.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.975
Number of shares100
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.01
Usd Total Gains Per Share0.020.01
Gains per Quarter (100 shares)2.341.45
Gains per Year (100 shares)9.365.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109-106-4
201980122
3028170178
40372602314
50473502920
60564403526
70665304132
80756204738
90847105244
100948005850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%17.017.06.042.5%17.017.012.037.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%8.010.02.040.0%24.014.02.060.0%27.017.02.058.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%8.010.02.040.0%24.014.02.060.0%27.017.02.058.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Hyundai Bioscience Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--354.70433.419+961%-47.982+114%20.768+1608%25.189+1308%
Book Value Per Share--1520.2381290.736+18%1503.043+1%1389.636+9%1042.365+46%
Current Ratio--0.7251.976-63%3.019-76%3.039-76%2.018-64%
Debt To Asset Ratio--0.4270.207+106%0.126+238%0.245+74%0.330+30%
Debt To Equity Ratio--0.9130.344+165%0.145+530%0.375+144%0.585+56%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--686314027000.000927545150232.500-26%958476065795.000-28%928674092145.000-26%587502883965.750+17%
Eps--57.937-41.267+171%-19.935+134%-58.415+201%-24.505+142%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--156.950143.410+9%99.286+58%106.945+47%57.183+174%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.850+18%
Market Cap567426450000.000-29%731482378000.000944416619500.000-23%952181402500.000-23%936114274600.000-22%601173391500.000+22%
Net Profit Margin--2.110-1.449+169%-1.621+177%-1.479+170%-0.719+134%
Operating Margin----0%-0.9430%-0.6110%-0.2920%
Operating Ratio--1.8552.583-28%2.567-28%1.477+26%1.241+50%
Pb Ratio9.374-29%12.08418.749-36%16.118-25%17.013-29%13.343-9%
Pe Ratio61.489-29%79.26618.905+319%-69.780+188%-105.952+234%41.343+92%
Price Per Share14250.000-29%18370.00023717.500-23%23912.500-23%23509.000-22%15097.500+22%
Price To Free Cash Flow Ratio----96.4510%-161.3390%-258.1130%-91.2870%
Price To Total Gains Ratio40.174-29%51.7905.501+841%-306.638+692%-587.452+1234%-56.129+208%
Quick Ratio---0.945-100%3.801-100%2.904-100%2.024-100%
Return On Assets--0.022-0.035+262%-0.048+321%-0.039+279%-0.016+172%
Return On Equity--0.047-0.036+177%-0.055+219%-0.050+207%-0.019+141%
Total Gains Per Share--354.70433.419+961%-47.982+114%20.768+1608%25.189+1308%
Usd Book Value--42374472.00035977444.335+18%41895200.713+1%38734136.076+9%29054450.595+46%
Usd Book Value Change Per Share--0.2480.023+961%-0.034+114%0.015+1608%0.018+1308%
Usd Book Value Per Share--1.0640.904+18%1.052+1%0.973+9%0.730+46%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--480419818.900649281605.163-26%670933246.057-28%650071864.502-26%411252018.776+17%
Usd Eps--0.041-0.029+171%-0.014+134%-0.041+201%-0.017+142%
Usd Free Cash Flow----1938317.0560%-2842243.0930%-2398318.4470%-1216242.0780%
Usd Market Cap397198515.000-29%512037664.600661091633.650-23%666526981.750-23%655279992.220-22%420821374.050+22%
Usd Price Per Share9.975-29%12.85916.602-23%16.739-23%16.456-22%10.568+22%
Usd Profit--1614925.200-1150259.698+171%-2139260.296+232%-1944957.782+220%-841411.866+152%
Usd Revenue--765244.9001616965.348-53%1834130.120-58%2083219.296-63%4054786.010-81%
Usd Total Gains Per Share--0.2480.023+961%-0.034+114%0.015+1608%0.018+1308%
 EOD+3 -4MRQTTM+18 -11YOY+18 -115Y+17 -1210Y+22 -8

3.3 Fundamental Score

Let's check the fundamental score of Hyundai Bioscience Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1561.489
Price to Book Ratio (EOD)Between0-19.374
Net Profit Margin (MRQ)Greater than02.110
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.725
Debt to Asset Ratio (MRQ)Less than10.427
Debt to Equity Ratio (MRQ)Less than10.913
Return on Equity (MRQ)Greater than0.150.047
Return on Assets (MRQ)Greater than0.050.022
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Hyundai Bioscience Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.096
Ma 20Greater thanMa 5014,372.000
Ma 50Greater thanMa 10015,889.200
Ma 100Greater thanMa 20017,653.800
OpenGreater thanClose14,120.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Hyundai Bioscience Co. Ltd

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 17:09:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Hyundai Bioscience Co. Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 211.0% means that ₩2.11 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 211.0%. The company is making a huge profit. +2
  • The TTM is -144.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ211.0%TTM-144.9%+355.9%
TTM-144.9%YOY-162.1%+17.3%
TTM-144.9%5Y-147.9%+3.0%
5Y-147.9%10Y-71.9%-76.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ211.0%-108.6%+319.6%
TTM-144.9%-220.8%+75.9%
YOY-162.1%-207.5%+45.4%
5Y-147.9%-350.0%+202.1%
10Y-71.9%-473.2%+401.3%
4.3.1.2. Return on Assets

Shows how efficient Hyundai Bioscience Co. Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • 2.2% Return on Assets means that Hyundai Bioscience Co. Ltd generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is -3.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.2%TTM-3.5%+5.7%
TTM-3.5%YOY-4.8%+1.3%
TTM-3.5%5Y-3.9%+0.4%
5Y-3.9%10Y-1.6%-2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2%-11.6%+13.8%
TTM-3.5%-11.9%+8.4%
YOY-4.8%-11.2%+6.4%
5Y-3.9%-12.6%+8.7%
10Y-1.6%-14.2%+12.6%
4.3.1.3. Return on Equity

Shows how efficient Hyundai Bioscience Co. Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • 4.7% Return on Equity means Hyundai Bioscience Co. Ltd generated ₩0.05 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 4.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -3.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.7%TTM-3.6%+8.2%
TTM-3.6%YOY-5.5%+2.0%
TTM-3.6%5Y-5.0%+1.4%
5Y-5.0%10Y-1.9%-3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7%-14.3%+19.0%
TTM-3.6%-15.9%+12.3%
YOY-5.5%-14.7%+9.2%
5Y-5.0%-18.5%+13.5%
10Y-1.9%-19.2%+17.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Hyundai Bioscience Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Hyundai Bioscience Co. Ltd is operating .

  • Measures how much profit Hyundai Bioscience Co. Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-94.3%+94.3%
TTM-5Y-61.1%+61.1%
5Y-61.1%10Y-29.2%-31.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM--316.3%+316.3%
YOY-94.3%-216.2%+121.9%
5Y-61.1%-379.8%+318.7%
10Y-29.2%-480.9%+451.7%
4.3.2.2. Operating Ratio

Measures how efficient Hyundai Bioscience Co. Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.86 means that the operating costs are ₩1.86 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 1.855. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.583. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.855TTM2.583-0.728
TTM2.583YOY2.567+0.017
TTM2.5835Y1.477+1.107
5Y1.47710Y1.241+0.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8552.284-0.429
TTM2.5833.244-0.661
YOY2.5673.247-0.680
5Y1.4774.764-3.287
10Y1.2416.437-5.196
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Hyundai Bioscience Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Hyundai Bioscience Co. Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.72 means the company has ₩0.72 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.725. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.976. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.725TTM1.976-1.251
TTM1.976YOY3.019-1.044
TTM1.9765Y3.039-1.063
5Y3.03910Y2.018+1.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7253.586-2.861
TTM1.9763.865-1.889
YOY3.0194.644-1.625
5Y3.0395.968-2.929
10Y2.0186.215-4.197
4.4.3.2. Quick Ratio

Measures if Hyundai Bioscience Co. Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.945-0.945
TTM0.945YOY3.801-2.856
TTM0.9455Y2.904-1.959
5Y2.90410Y2.024+0.881
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.099-3.099
TTM0.9453.384-2.439
YOY3.8014.304-0.503
5Y2.9045.954-3.050
10Y2.0246.436-4.412
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Hyundai Bioscience Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Hyundai Bioscience Co. Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hyundai Bioscience Co. Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Hyundai Bioscience Co. Ltd assets are financed with 42.7% credit (debt) and the remaining percentage (100% - 42.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.427. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.207. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.427TTM0.207+0.220
TTM0.207YOY0.126+0.081
TTM0.2075Y0.245-0.038
5Y0.24510Y0.330-0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4270.346+0.081
TTM0.2070.346-0.139
YOY0.1260.314-0.188
5Y0.2450.365-0.120
10Y0.3300.383-0.053
4.5.4.2. Debt to Equity Ratio

Measures if Hyundai Bioscience Co. Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 91.3% means that company has ₩0.91 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.913. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.344. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.913TTM0.344+0.568
TTM0.344YOY0.145+0.199
TTM0.3445Y0.375-0.031
5Y0.37510Y0.585-0.210
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9130.393+0.520
TTM0.3440.432-0.088
YOY0.1450.390-0.245
5Y0.3750.452-0.077
10Y0.5850.498+0.087
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Hyundai Bioscience Co. Ltd generates.

  • Above 15 is considered overpriced but always compare Hyundai Bioscience Co. Ltd to the Biotechnology industry mean.
  • A PE ratio of 79.27 means the investor is paying ₩79.27 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hyundai Bioscience Co. Ltd:

  • The EOD is 61.489. Based on the earnings, the company is expensive. -2
  • The MRQ is 79.266. Based on the earnings, the company is expensive. -2
  • The TTM is 18.905. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD61.489MRQ79.266-17.778
MRQ79.266TTM18.905+60.362
TTM18.905YOY-69.780+88.684
TTM18.9055Y-105.952+124.856
5Y-105.95210Y41.343-147.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD61.489-2.123+63.612
MRQ79.266-2.548+81.814
TTM18.905-3.161+22.066
YOY-69.780-3.244-66.536
5Y-105.952-6.006-99.946
10Y41.343-6.717+48.060
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hyundai Bioscience Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-96.451+96.451
TTM-96.451YOY-161.339+64.888
TTM-96.4515Y-258.113+161.661
5Y-258.11310Y-91.287-166.826
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--3.295+3.295
TTM-96.451-3.674-92.777
YOY-161.339-4.477-156.862
5Y-258.113-8.046-250.067
10Y-91.287-9.204-82.083
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Hyundai Bioscience Co. Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 12.08 means the investor is paying ₩12.08 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Hyundai Bioscience Co. Ltd:

  • The EOD is 9.374. Based on the equity, the company is overpriced. -1
  • The MRQ is 12.084. Based on the equity, the company is expensive. -2
  • The TTM is 18.749. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.374MRQ12.084-2.710
MRQ12.084TTM18.749-6.665
TTM18.749YOY16.118+2.631
TTM18.7495Y17.013+1.735
5Y17.01310Y13.343+3.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.3741.919+7.455
MRQ12.0842.055+10.029
TTM18.7492.389+16.360
YOY16.1182.454+13.664
5Y17.0133.716+13.297
10Y13.3434.373+8.970
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Net Working Capital  13,163,221-1,728,70211,434,519-3,218,6908,215,8291,241,8509,457,679-21,190,044-11,732,365



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets105,703,311
Total Liabilities45,168,351
Total Stockholder Equity49,495,015
 As reported
Total Liabilities 45,168,351
Total Stockholder Equity+ 49,495,015
Total Assets = 105,703,311

Assets

Total Assets105,703,311
Total Current Assets30,917,883
Long-term Assets74,785,428
Total Current Assets
Total Current Assets  (as reported)30,917,883
Total Current Assets  (calculated)0
+/- 30,917,883
Long-term Assets
Long-term Assets  (as reported)74,785,428
Long-term Assets  (calculated)0
+/- 74,785,428

Liabilities & Shareholders' Equity

Total Current Liabilities42,650,248
Long-term Liabilities2,518,103
Total Stockholder Equity49,495,015
Total Current Liabilities
Total Current Liabilities  (as reported)42,650,248
Total Current Liabilities  (calculated)0
+/- 42,650,248
Long-term Liabilities
Long-term Liabilities  (as reported)2,518,103
Long-term Liabilities  (calculated)0
+/- 2,518,103
Total Stockholder Equity
Total Stockholder Equity (as reported)49,495,015
Total Stockholder Equity (calculated)0
+/- 49,495,015
Other
Common Stock Shares Outstanding 39,818
Net Invested Capital 49,495,015
Net Working Capital -11,732,365



6.3. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
31,106,103
26,319,132
32,137,644
30,842,884
31,335,588
29,047,246
31,063,319
32,807,087
37,628,466
34,160,410
35,362,800
43,413,787
46,509,134
46,391,835
55,179,007
53,381,061
49,911,540
49,191,365
51,881,761
49,498,781
50,036,539
51,355,553
51,219,536
54,008,494
64,306,023
64,274,872
65,212,209
63,235,589
0
0
96,721,060
92,311,468
94,173,536
95,739,900
92,752,934
80,528,216
78,234,739
73,336,614
79,161,356
67,326,811
65,607,528
62,087,811
60,845,527
52,791,761
53,730,675
105,703,311
105,703,31153,730,67552,791,76160,845,52762,087,81165,607,52867,326,81179,161,35673,336,61478,234,73980,528,21692,752,93495,739,90094,173,53692,311,46896,721,0600063,235,58965,212,20964,274,87264,306,02354,008,49451,219,53651,355,55350,036,53949,498,78151,881,76149,191,36549,911,54053,381,06155,179,00746,391,83546,509,13443,413,78735,362,80034,160,41037,628,46632,807,08731,063,31929,047,24631,335,58830,842,88432,137,64426,319,13231,106,103
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,042,393
36,809,022
36,368,306
37,621,367
39,958,570
40,045,255
35,691,687
35,664,348
33,738,548
34,819,066
33,268,973
33,558,353
36,912,830
68,526,138
41,859,904
43,401,155
41,737,014
38,810,119
34,850,764
32,254,854
26,272,364
35,646,459
24,012,071
22,229,982
19,905,918
18,636,293
15,162,589
16,174,621
30,917,883
30,917,88316,174,62115,162,58918,636,29319,905,91822,229,98224,012,07135,646,45926,272,36432,254,85434,850,76438,810,11941,737,01443,401,15541,859,90468,526,13836,912,83033,558,35333,268,97334,819,06633,738,54835,664,34835,691,68740,045,25539,958,57037,621,36736,368,30636,809,02234,042,39300000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,093,356
6,685,240
4,850,550
2,792,970
2,506,539
3,197,926
3,162,374
5,985,110
10,595,324
1,870,899
5,555,134
0
0
33,882,119
19,211,208
14,763,435
16,668,668
4,014,586
0
7,320
0
1,500
2,732,425
8,291
4,591,787
3,401,953
1,811,880
3,864,544
0
03,864,5441,811,8803,401,9534,591,7878,2912,732,4251,50007,32004,014,58616,668,66814,763,43519,211,20833,882,119005,555,1341,870,89910,595,3245,985,1103,162,3743,197,9262,506,5392,792,9704,850,5506,685,2408,093,35600000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,000,000
0
6,500,000
1,500,000
0
0
0
0
8,000,000
13,000,000
23,010,434
13,010,434
17,021,002
14,029,755
19,040,521
16,000,000
13,000,000
11,000,000
10,000,000
10,000,000
0
0
0010,000,00010,000,00011,000,00013,000,00016,000,00019,040,52114,029,75517,021,00213,010,43423,010,43413,000,0008,000,00000001,500,0006,500,00004,000,000000000000000000000000000
       Net Receivables 
7,344,957
3,425,284
3,824,968
4,550,096
6,544,901
7,728,749
9,584,546
8,581,664
11,172,770
11,032,434
12,810,785
12,196,083
16,076,323
11,765,280
12,709,794
13,368,390
10,382,450
12,797,571
14,668,864
19,684,057
22,657,182
29,303,277
30,782,048
25,891,962
18,747,519
17,837,755
20,761,421
19,385,967
20,140,241
24,781,962
24,992,592
17,250,030
15,770,238
7,290,989
7,390,389
7,671,385
9,903,814
6,600,654
7,679,664
1,323,865
2,587,541
1,593,585
2,258,518
446,212
3,864,262
0
03,864,262446,2122,258,5181,593,5852,587,5411,323,8657,679,6646,600,6549,903,8147,671,3857,390,3897,290,98915,770,23817,250,03024,992,59224,781,96220,140,24119,385,96720,761,42117,837,75518,747,51925,891,96230,782,04829,303,27722,657,18219,684,05714,668,86412,797,57110,382,45013,368,39012,709,79411,765,28016,076,32312,196,08312,810,78511,032,43411,172,7708,581,6649,584,5467,728,7496,544,9014,550,0963,824,9683,425,2847,344,957
       Other Current Assets 
2,063,694
1,699,587
4,176,841
4,754,915
5,881,854
4,059,269
3,466,540
3,655,849
6,058,274
3,871,351
5,205,403
3,591,426
5,646,392
4,756,563
5,640,583
3,590,995
4,648,641
4,777,760
5,532,887
3,297,433
2,991,739
1,580,456
1,429,144
2,151,683
1,567,061
510,102
193,055
281,581
3,470,226
75,627
4,609,646
984,996
123,501
122,738
142,171
0
0
79,914
82,226
0
109,440
0
0
-1
0
0
00-100109,440082,22679,91400142,171122,738123,501984,9964,609,64675,6273,470,226281,581193,055510,1021,567,0612,151,6831,429,1441,580,4562,991,7393,297,4335,532,8874,777,7604,648,6413,590,9955,640,5834,756,5635,646,3923,591,4265,205,4033,871,3516,058,2743,655,8493,466,5404,059,2695,881,8544,754,9154,176,8411,699,5872,063,694
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
42,696,921
43,377,546
42,181,893
42,209,234
37,629,172
37,556,053
74,785,428
74,785,42837,556,05337,629,17242,209,23442,181,89343,377,54642,696,921000000000000000000000000000000000000000
       Property Plant Equipment 
6,759,707
6,289,049
5,928,032
5,709,243
5,493,112
5,345,365
5,925,947
5,707,219
5,548,658
5,380,652
5,487,416
5,417,899
5,222,941
7,620,733
8,867,563
10,080,968
9,843,095
9,655,765
9,709,222
9,436,650
9,088,826
9,016,123
8,689,220
8,369,945
7,968,584
7,996,570
7,606,800
7,196,074
6,790,482
6,453,819
6,869,274
6,673,591
6,485,670
6,414,881
6,201,519
6,072,666
6,029,473
6,309,759
6,377,550
6,375,625
6,586,943
6,376,687
6,586,372
2,903,743
2,783,795
0
02,783,7952,903,7436,586,3726,376,6876,586,9436,375,6256,377,5506,309,7596,029,4736,072,6666,201,5196,414,8816,485,6706,673,5916,869,2746,453,8196,790,4827,196,0747,606,8007,996,5707,968,5848,369,9458,689,2209,016,1239,088,8269,436,6509,709,2229,655,7659,843,09510,080,9688,867,5637,620,7335,222,9415,417,8995,487,4165,380,6525,548,6585,707,2195,925,9475,345,3655,493,1125,709,2435,928,0326,289,0496,759,707
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
805,687
767,792
571,513
296,156
95,573
599,009
1,155,848
1,218,900
1,519,072
2,434,351
1,974,445
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,974,4452,434,3511,519,0721,218,9001,155,848599,00995,573296,156571,513767,792805,68700000000000000000
       Intangible Assets 
387,982
383,821
379,754
370,722
369,851
369,303
664,049
695,398
677,681
659,994
642,320
624,667
607,016
2,404,513
2,312,311
2,220,132
2,128,000
2,035,882
1,943,770
1,851,657
1,759,546
1,667,455
1,575,405
8,483,355
18,076,804
19,513,006
18,955,040
19,408,740
0
0
17,769,840
39,394,586
39,025,987
41,657,388
41,303,910
33,664,467
33,542,025
33,419,583
33,297,064
33,174,622
33,092,461
32,989,829
32,941,937
31,169,921
31,169,921
0
031,169,92131,169,92132,941,93732,989,82933,092,46133,174,62233,297,06433,419,58333,542,02533,664,46741,303,91041,657,38839,025,98739,394,58617,769,8400019,408,74018,955,04019,513,00618,076,8048,483,3551,575,4051,667,4551,759,5461,851,6571,943,7702,035,8822,128,0002,220,1322,312,3112,404,513607,016624,667642,320659,994677,681695,398664,049369,303369,851370,722379,754383,821387,982
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
00000-10000000000000000000000000000000000000000
> Total Liabilities 
13,528,293
11,167,697
10,421,130
9,039,310
10,266,136
8,632,128
10,449,567
10,321,692
14,990,471
11,224,768
11,482,127
18,808,811
21,763,329
21,518,247
31,439,507
35,166,554
32,847,138
27,075,262
23,340,341
18,607,939
19,272,913
20,277,834
14,800,124
13,524,026
20,826,312
20,279,690
17,358,967
16,245,755
0
0
37,952,554
41,088,623
43,110,217
43,980,205
24,584,827
18,957,444
10,762,184
10,482,098
10,226,380
9,091,422
8,588,742
6,875,814
7,476,944
7,520,749
7,319,834
45,168,351
45,168,3517,319,8347,520,7497,476,9446,875,8148,588,7429,091,42210,226,38010,482,09810,762,18418,957,44424,584,82743,980,20543,110,21741,088,62337,952,5540016,245,75517,358,96720,279,69020,826,31213,524,02614,800,12420,277,83419,272,91318,607,93923,340,34127,075,26232,847,13835,166,55431,439,50721,518,24721,763,32918,808,81111,482,12711,224,76814,990,47110,321,69210,449,5678,632,12810,266,1369,039,31010,421,13011,167,69713,528,293
   > Total Current Liabilities 
12,820,244
10,500,402
9,630,457
8,721,144
10,065,213
8,344,106
10,072,534
9,945,349
14,618,030
10,761,398
10,974,766
9,707,388
12,414,380
9,827,377
12,506,550
27,903,895
25,372,435
26,859,340
23,078,823
18,481,668
19,067,618
18,197,757
12,603,584
11,436,835
12,731,583
18,372,020
15,369,499
14,532,509
6,588,965
8,928,707
9,669,402
9,576,811
10,727,301
40,577,982
21,449,434
16,652,363
8,716,137
9,136,299
9,799,819
8,384,035
8,471,514
6,742,696
7,201,773
6,946,760
6,716,943
42,650,248
42,650,2486,716,9436,946,7607,201,7736,742,6968,471,5148,384,0359,799,8199,136,2998,716,13716,652,36321,449,43440,577,98210,727,3019,576,8119,669,4028,928,7076,588,96514,532,50915,369,49918,372,02012,731,58311,436,83512,603,58418,197,75719,067,61818,481,66823,078,82326,859,34025,372,43527,903,89512,506,5509,827,37712,414,3809,707,38810,974,76610,761,39814,618,0309,945,34910,072,5348,344,10610,065,2138,721,1449,630,45710,500,40212,820,244
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,523,324
17,732,454
16,377,696
15,948,548
250,000
4,638,835
500,000
375,000
500,000
500,000
500,000
0
0
6,400,000
6,400,000
6,400,000
6,400,000
6,400,000
6,400,000
6,400,000
6,400,000
6,400,000
5,900,000
5,900,000
0
0
0
0
0
000005,900,0005,900,0006,400,0006,400,0006,400,0006,400,0006,400,0006,400,0006,400,0006,400,0006,400,00000500,000500,000500,000375,000500,0004,638,835250,00015,948,54816,377,69617,732,45421,523,32400000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,523,324
17,732,454
16,377,696
15,948,548
250,000
4,638,835
500,000
375,000
500,000
500,000
500,000
0
0
0
0
0
0
0
0
0
0
0
6,011,080
5,927,770
5,400,000
5,400,000
5,400,000
5,400,000
0
05,400,0005,400,0005,400,0005,400,0005,927,7706,011,08000000000000500,000500,000500,000375,000500,0004,638,835250,00015,948,54816,377,69617,732,45421,523,32400000000000000000
       Accounts payable 
2,436,729
2,360,846
1,778,821
2,027,602
3,622,289
2,150,452
3,489,547
3,691,880
4,637,745
2,240,559
3,830,459
2,844,668
2,765,480
2,265,255
5,623,700
3,453,942
2,866,875
2,497,827
2,276,348
603,820
1,665,308
1,867,503
953,654
389,526
1,174,763
1,840,525
1,766,229
827,757
293,510
352,233
129,818
178,173
363,444
751,543
413,721
0
0
343,413
831,739
686,719
665,270
487,686
647,979
430,520
406,998
0
0406,998430,520647,979487,686665,270686,719831,739343,41300413,721751,543363,444178,173129,818352,233293,510827,7571,766,2291,840,5251,174,763389,526953,6541,867,5031,665,308603,8202,276,3482,497,8272,866,8753,453,9425,623,7002,265,2552,765,4802,844,6683,830,4592,240,5594,637,7453,691,8803,489,5472,150,4523,622,2892,027,6021,778,8212,360,8462,436,729
       Other Current Liabilities 
2,042,402
1,710,553
2,434,473
1,650,667
1,531,770
1,275,254
1,675,785
1,353,469
2,749,626
2,245,802
1,924,059
1,962,720
1,846,357
2,662,122
1,982,850
4,145,363
3,114,899
2,838,189
3,070,021
1,500,152
1,453,762
1,081,783
1,598,178
2,568,868
3,489,713
1,149,525
1,035,409
1,144,654
1,073,386
1,037,585
1,566,047
1,651,868
2,717,489
2,199,109
1,218,559
0
0
1,375,403
1,824,015
874
1,508,727
864
872
858
874
0
08748588728641,508,7278741,824,0151,375,403001,218,5592,199,1092,717,4891,651,8681,566,0471,037,5851,073,3861,144,6541,035,4091,149,5253,489,7132,568,8681,598,1781,081,7831,453,7621,500,1523,070,0212,838,1893,114,8994,145,3631,982,8502,662,1221,846,3571,962,7201,924,0592,245,8022,749,6261,353,4691,675,7851,275,2541,531,7701,650,6672,434,4731,710,5532,042,402
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,930
725,686
133,117
275,170
573,989
602,891
2,518,103
2,518,103602,891573,989275,170133,117725,68698,930000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,481,748
29,534,979
30,156,763
867,397
576,347
285,772
131,243
26,427
64,945
41,698
59,996
0
0
0
0
0
0000059,99641,69864,94526,427131,243285,772576,347867,39730,156,76329,534,97927,481,748000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-21,523,324
-17,732,454
-16,377,696
-15,948,548
-250,000
-4,638,835
-500,000
-375,000
-500,000
-500,000
-500,000
0
0
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-6,400,000
-5,662,137
-5,689,558
199,016
590,579
146,535
133,697
0
0133,697146,535590,579199,016-5,689,558-5,662,137-6,400,000-6,400,000-6,400,000-6,400,000-6,400,000-6,400,000-6,400,000-6,400,000-6,400,00000-500,000-500,000-500,000-375,000-500,000-4,638,835-250,000-15,948,548-16,377,696-17,732,454-21,523,32400000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000
> Total Stockholder Equity
17,577,809
15,151,435
21,716,514
21,803,574
21,069,452
20,415,117
20,613,752
22,485,396
22,637,994
22,935,642
23,880,673
24,604,975
24,745,805
24,873,589
23,739,500
18,214,507
17,064,402
22,116,103
28,541,420
30,890,842
30,763,626
31,077,719
36,419,412
40,484,468
43,479,712
43,995,181
47,853,242
46,989,834
0
0
58,768,506
51,222,845
51,063,319
51,759,695
68,168,107
61,570,772
67,472,555
62,854,515
68,934,976
58,235,389
57,018,785
55,211,997
53,368,583
45,271,012
46,410,841
49,495,015
49,495,01546,410,84145,271,01253,368,58355,211,99757,018,78558,235,38968,934,97662,854,51567,472,55561,570,77268,168,10751,759,69551,063,31951,222,84558,768,5060046,989,83447,853,24243,995,18143,479,71240,484,46836,419,41231,077,71930,763,62630,890,84228,541,42022,116,10317,064,40218,214,50723,739,50024,873,58924,745,80524,604,97523,880,67322,935,64222,637,99422,485,39620,613,75220,415,11721,069,45221,803,57421,716,51415,151,43517,577,809
   Common Stock
10,234,202
10,234,202
13,234,202
14,860,227
14,860,227
14,860,227
14,860,227
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,148,877
15,630,664
16,241,823
16,287,096
16,287,096
16,287,096
16,697,549
16,859,430
17,008,230
17,092,230
17,318,596
17,322,846
17,957,939
17,957,939
17,957,939
17,957,939
18,078,939
18,275,639
19,119,963
115,688,745
19,659,004
19,739,004
19,841,354
129,399,400
19,894,854
0
0
0
0
0
0000019,894,854129,399,40019,841,35419,739,00419,659,004115,688,74519,119,96318,275,63918,078,93917,957,93917,957,93917,957,93917,957,93917,322,84617,318,59617,092,23017,008,23016,859,43016,697,54916,287,09616,287,09616,287,09616,241,82315,630,66415,148,87715,148,87715,148,87715,148,87715,148,87715,148,87715,148,87715,148,87715,148,87715,148,87714,860,22714,860,22714,860,22714,860,22713,234,20210,234,20210,234,202
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
116,373,985
51,608,430
117,777,533
120,229,685
137,143,366
46,310,767
150,464,616
45,180,947
154,738,993
45,180,947
47,801,631
0
0
0
0
0
0000047,801,63145,180,947154,738,99345,180,947150,464,61646,310,767137,143,366120,229,685117,777,53351,608,430116,373,985000000000000000000000000000000
   Treasury Stock
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
-4,038
0
0
0
0
0
0
0
-4,038
-4,038
-4,038
-4,038
1,144,945
-4,038
0
0
0
0
0
0
0
0
0
0
0000000000-4,0381,144,945-4,038-4,038-4,038-4,0380000000-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038-4,038
   Other Stockholders Equity 00000-1,001,505-11,457,243-1,235,868-1,512,479-11,386,722-11,354,019-749,463-887,399-399,936-116,859-549,604-500,438-1,030,813-1,072,846-1,433,790-1,386,060-1,244,566-619,883-1,216,754-1,353,226-2,216,633-1,312,711-1,818,270-1,995,22100000000000000000



6.4. Balance Sheets

Currency in KRW. All numbers in thousands.




6.5. Cash Flows

Currency in KRW. All numbers in thousands.




6.6. Income Statements

Currency in KRW. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue9,481,385
Cost of Revenue-4,440,200
Gross Profit5,041,1845,041,184
 
Operating Income (+$)
Gross Profit5,041,184
Operating Expense-19,266,533
Operating Income-9,785,149-14,225,349
 
Operating Expense (+$)
Research Development6,401,202
Selling General Administrative3,423,982
Selling And Marketing Expenses0
Operating Expense19,266,5339,825,184
 
Net Interest Income (+$)
Interest Income669,192
Interest Expense-314,573
Other Finance Cost-0
Net Interest Income354,619
 
Pretax Income (+$)
Operating Income-9,785,149
Net Interest Income354,619
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-14,498,313-9,785,149
EBIT - interestExpense = -314,573
-14,499,358
-14,184,785
Interest Expense314,573
Earnings Before Interest and Taxes (EBIT)0-14,183,741
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-14,498,313
Tax Provision-1,044
Net Income From Continuing Ops-14,499,358-14,499,358
Net Income-14,499,358
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-354,619
 

Technical Analysis of Hyundai Bioscience Co. Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hyundai Bioscience Co. Ltd. The general trend of Hyundai Bioscience Co. Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hyundai Bioscience Co. Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hyundai Bioscience Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16,590 < 16,700 < 17,730.

The bearish price targets are: 12,650.

Tweet this
Hyundai Bioscience Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hyundai Bioscience Co. Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hyundai Bioscience Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hyundai Bioscience Co. Ltd. The current macd is -304.44892178.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hyundai Bioscience Co. Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hyundai Bioscience Co. Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hyundai Bioscience Co. Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hyundai Bioscience Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartHyundai Bioscience Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hyundai Bioscience Co. Ltd. The current adx is 20.91.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hyundai Bioscience Co. Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Hyundai Bioscience Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hyundai Bioscience Co. Ltd. The current sar is 13,810.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Hyundai Bioscience Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hyundai Bioscience Co. Ltd. The current rsi is 45.10. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Hyundai Bioscience Co. Ltd Daily Relative Strength Index (RSI) ChartHyundai Bioscience Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hyundai Bioscience Co. Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hyundai Bioscience Co. Ltd price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Hyundai Bioscience Co. Ltd Daily Stochastic Oscillator ChartHyundai Bioscience Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hyundai Bioscience Co. Ltd. The current cci is -32.53968254.

Hyundai Bioscience Co. Ltd Daily Commodity Channel Index (CCI) ChartHyundai Bioscience Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hyundai Bioscience Co. Ltd. The current cmo is -8.32051972.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hyundai Bioscience Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartHyundai Bioscience Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hyundai Bioscience Co. Ltd. The current willr is -57.78364116.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hyundai Bioscience Co. Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hyundai Bioscience Co. Ltd Daily Williams %R ChartHyundai Bioscience Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hyundai Bioscience Co. Ltd.

Hyundai Bioscience Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hyundai Bioscience Co. Ltd. The current atr is 904.16.

Hyundai Bioscience Co. Ltd Daily Average True Range (ATR) ChartHyundai Bioscience Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hyundai Bioscience Co. Ltd. The current obv is 27,688,723.

Hyundai Bioscience Co. Ltd Daily On-Balance Volume (OBV) ChartHyundai Bioscience Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hyundai Bioscience Co. Ltd. The current mfi is 48.04.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hyundai Bioscience Co. Ltd Daily Money Flow Index (MFI) ChartHyundai Bioscience Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hyundai Bioscience Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Hyundai Bioscience Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hyundai Bioscience Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.096
Ma 20Greater thanMa 5014,372.000
Ma 50Greater thanMa 10015,889.200
Ma 100Greater thanMa 20017,653.800
OpenGreater thanClose14,120.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Hyundai Bioscience Co. Ltd with someone you think should read this too:
  • Are you bullish or bearish on Hyundai Bioscience Co. Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hyundai Bioscience Co. Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hyundai Bioscience Co. Ltd

I send you an email if I find something interesting about Hyundai Bioscience Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Hyundai Bioscience Co. Ltd.

Receive notifications about Hyundai Bioscience Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.